Event Details

Join us and others in the cell immunotherapy revolution to engineer a cancer-free world. Let’s e-meet during the CAR-TCR Digital Week (Virtual Event, September 14-17) and discuss recent advances from discovery, clinical trials through to late-stage manufacturing.


Monday, September 14, 11.35am PDT (2.35pm EDT/ 8.35pm CEST)

Session: Innovative Target Identification to Define Clinically Beneficial & Safe Targets

Presentation: TCR-T Therapies Using Novel Solid Cancer Targets

• TCR-T Therapies for Solid Tumors Using Novel Targets
• Assess the discovery, characterization and engineering of TCRs using the XCEPTORTM platform directed against novel targets derived from the XPRESIDENT® platform
• Preclinical Update on Immatics’ ACTengine® program IMA204

Presenter: Steffen Walter, CTO Immatics

Thursday, September 17, 11.05am PDT (2.05pm EDT/ 8.05pm CEST)

Session: Scaling-Up for Late Stage Trials & Commercial Capacity

Presentation: Manufacturing Platforms for Endogenous, Engineered, Autologous or Allogeneic TCR-T based Adoptive Cell Therapies

• Extensive process development led to the manufacturing approaches for various product platforms
• Exemplary manufacturing and/ or clinical data from various trials will be presented for the various platforms

Presenter: Ali Mohamed, VP CMC Immatics

Thursday, September 17, 12.05am PDT (3.05pm EDT/ 9.05pm CEST)
Session: Scaling-Up for Late Stage Trials & Commercial Capacity

Panel Discussion: Live Q&A with Speakers
Use this opportunity to ask your expert speakers your burning questions

Speaker:
John Lunger, CPSO Adaptimmune
Ali Mohamed, VP CMC Immatics
Madhusudan Peshwa, CTO Mana Therapeutics

We are looking forward to e-meeting you!

Learn more about the Hanson Wade CAR-TCR Digital Week here.